Indications |
Subcutaneous Palliative treatment of prostatic carcinoma Adult: 3.6 mg injected into the anterior abdominal wall every 28 days or 10.8 mg every 12 wk. An anti-androgen is given several days before beginning of the treatment and continued for at least 3 wk to prevent disease flare. Subcutaneous Pituitary desensitisation before ovulation induction with gonadotrophins Adult: 3.6 mg as a depot inj. Monitor serum-oestradiol concentrations until they decline to levels similar to those in the early follicular phase which takes about 7-21 days. |
Contraindications |
Hypersensitivity; pregnancy, lactation. |
Warnings / Precautions |
Urinary tract obstruction or spinal cord compression (when used for prostate cancer); decreased bone density in women. Contraceptive measures should be taken to protect against pregnancy. Monitor men at risk from tumour flare during the 1st mth of therapy. Safety and efficacy on the usage of the 10.8 mg implant in women is not established. |
Adverse Reactions |
Vaginal bleeding and dryness, arthralgia, paraesthesias, increase in menstrual bleeding, hot flushes, sexual dysfunction. Headache, emotional lability, depression, insomnia, diaphoresis, dizziness, breast swelling/tenderness, Inj site reactions. Anaphylaxis. |
Mechanism of Actions |
Goserelin is a potent inhibitor of pituitary gonadotrophin secretion. Initially, it causes an increase in the serum levels of FSH and LH but chronic admin will lead to sustained suppression of the pituitary gonadotrophin release causing regression of the sex organs. Absorption: Almost complete (SC). Excretion: >90% excreted in urine (as unchanged drug and metabolites); 2-4 hr (elimination half-life). |
Storage Conditions |
Subcutaneous: Store below 25°C. |
ATC Classification |
L02AE03 - goserelin ; Belongs to the class of gonadotropin releasing hormone analogues. Used in endocrine therapy. |
Storage |
Subcutaneous: Store below 25°C. |
Available As |
|
Goserelin
Post Review about Goserelin Click here to cancel reply.
Goserelin Containing Brands
Goserelin is used in following diseases
Drug - Drug Interactions of Goserelin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.